Protocol Summary
Protocol No.LCCC1524-ATLPrincipal InvestigatorShea, Thomas
PhasePhase I
Oncology GroupHematology; Lymphoma; Phase 1Oncology Group
Management GroupCellular Immunotherapy CPO; Clinical Protocol Office; Lymphoma CPO
Age GroupBothScopeLocal
TitlePhase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas after High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Applicable Disease SitesHodgkin's Lymphoma
Non-Hodgkins Lymphoma
Drugs InvolvedATLCAR.CD30
Participating InstitutionsUNC-CH
Eligibility DocumentLCCC 1524-ATL Eligibility Criteria 11-10-16.pdf